Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.8K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.8K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

429
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
429
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.0K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Exploratory In Silico Analysis of <i>Chlamydia trachomatis</i>-Induced Inflammatory, Interferon, and ECM Transcriptional Programs and Their Translational Context in TCGA Ovarian Cancer.

Cancers·2026
Same author

Model-Based Virtual Clinical Trial Reveals Renal Impairment and Body Size as Key Determinants of Pharmacokinetic Variability and Drug-Drug Interaction Risk in Propranolol Therapy.

Pharmaceutics·2026
Same author

Repurposing Antiretroviral Drugs for Urological Cancers: Differential Effects of Protease Inhibitors and NNRTIs on Prostate and Bladder Cancer Cells.

Cells·2026
Same author

Dual-Acting Vitamin B<sub>3</sub>-Melanostatin Neuropeptide Hybrids as Potent Modulators of the Dopamine D<sub>2</sub> Receptors with Neuroprotective Activity.

Journal of medicinal chemistry·2026
Same author

Recent advances in the development of selective hMAO-B inhibitors for neurodegenerative diseases: An update from 2020 to present.

European journal of medicinal chemistry·2026
Same author

18 kDa TSPO-mediated neurosteroidogenesis controls cholesterol homeostasis in tuning microglia response to inflammatory stimulus.

Biochimica et biophysica acta. Molecular basis of disease·2026

Related Experiment Video

Updated: Sep 3, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K

Dostarlimab: A Review.

Bárbara Costa1,2, Nuno Vale1,2,3

  • 1OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.

Biomolecules
|July 27, 2022
PubMed
Summary
This summary is machine-generated.

Dostarlimab, a PD-1 monoclonal antibody, shows promise in treating mismatch repair deficient (dMMR) cancers. A trial reported a 100% remission rate in rectal cancer, expanding to other solid tumors.

Keywords:
anti-PD-1 antibodyclinical trialsdostarlimabimmunotherapy

More Related Videos

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.2K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Related Experiment Videos

Last Updated: Sep 3, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.2K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Dostarlimab is a programmed cell death protein 1 (PD-1) monoclonal antibody.
  • It is approved for adult patients with mismatch repair deficient (dMMR), recurrent or advanced endometrial cancer previously treated with a platinum-containing regimen.
  • The initial approval was based on tumor response rate and duration, pending further clinical benefit confirmation.

Purpose of the Study:

  • To review existing knowledge on Dostarlimab.
  • To explore its potential in monotherapy and combination treatments.
  • To highlight emerging applications in other dMMR cancers.

Main Methods:

  • Review of existing literature and clinical trial data.
  • Analysis of Dostarlimab's mechanism of action as a PD-1 inhibitor.
  • Examination of clinical trial results, including NCT04165772.

Main Results:

  • Dostarlimab demonstrated a 100% remission rate in a clinical trial for rectal cancer.
  • This suggests a successful strategy of matching tumor genetics with targeted therapy.
  • The clinical trial is ongoing and enrolling patients with gastric, prostate, and pancreatic cancers.

Conclusions:

  • Dostarlimab is recommended for rectal cancer treatment.
  • The drug's efficacy in dMMR cancers warrants further investigation.
  • Future research should focus on optimizing mono- and combination therapy strategies.